Enzon Pharmaceuticals Inc
OTC:ENZN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Enzon Pharmaceuticals Inc
Cash from Financing Activities
Enzon Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Enzon Pharmaceuticals Inc
OTC:ENZN
|
Cash from Financing Activities
-$1.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
29%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$12.7B
|
CAGR 3-Years
20%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$7.7B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
-$10.9B
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$2.3B
|
CAGR 3-Years
-222%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$3.7B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-30%
|
|
Enzon Pharmaceuticals Inc
Glance View
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cranford, New Jersey and currently employs 0 full-time employees. The firm intends to become an acquisition platform. The firm utilizes its net operating loss carryforwards (NOLs) and improves stockholder value. The company manages its source of royalty revenues from existing licensing arrangements with other companies.
See Also
What is Enzon Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
-1.3m
USD
Based on the financial report for Dec 31, 2025, Enzon Pharmaceuticals Inc's Cash from Financing Activities amounts to -1.3m USD.
What is Enzon Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
29%
Over the last year, the Cash from Financing Activities growth was 0%.
